Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

Abstract Background Aberrant DNA repair pathways contribute to malignant transformation or disease progression and the acquisition of drug resistance in multiple myeloma (MM); therefore, these pathways could be therapeutically exploited. Ribonucleotide reductase (RNR) is the rate-limiting enzyme for...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Yongsheng Xie, Yingcong Wang, Zhijian Xu, Yumeng Lu, Dongliang Song, Lu Gao, Dandan Yu, Bo Li, Gege Chen, Hui Zhang, Qilin Feng, Yong Zhang, Ke Hu, Cheng Huang, Yu Peng, Xiaosong Wu, Zhiyong Mao, Jimin Shao, Weiliang Zhu, Jumei Shi
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2022-05-01
Serier:	Journal of Biomedical Science
Fag:	4-Hydroxysalicylanilid Ribonucleotide reductase Deoxyribonucleotides DNA damage repair Multiple myeloma
Online adgang:	https://doi.org/10.1186/s12929-022-00813-2
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!